Scilex Holding Company
HealthcareNASDAQ:SCLX · NASDAQ Capital Market
-$0.20 today
Vol 0.12M · Avg 0.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
172.7%
avg 40.7%
ROIC
1031.6%
avg 176.9%
ROA
-98.3%
avg -69.7%
Analysis
ROIC is currently the strongest return metric at 1031.6% versus its period average of 176.9%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Henry H. Ji | Chief Executive Officer, President & Executive Chairman | $1.58M | — | 62 | $2.60M | 30.62% |
Stephen Ma | Senior Vice President, Chief Financial Officer, Chief Operating Officer, Corporate Secretary & Director | $718,783.00 | — | 53 | $650,000.00 | 7.65% |
Dmitri V. Lissin | Senior Vice President of Clinical Development and Medical Affairs & Interim Chief Medical Officer | $528,826.00 | — | 67 | — | — |
Suresh K. Khemani | Senior Vice President, Chief Commercial Officer & GM of Scilex Pharma | $456,820.00 | — | 66 | — | — |
Gigi DeGuzman | Vice President & Chief People Officer | — | — | — | — | — |
Suketu D. Desai | Interim Chief Technical Officer & Senior Vice President | — | — | 60 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$4.68M
Sells
4
$13.55M
Net Sentiment
$8.87M
Net selling
Most Active
Scilex Holding Co
3 transactions
Analysis
Insiders reported 2 buys worth $4.68M and 4 sells worth $13.55M over the last 12 months. That adds up to net selling of $8.87M. Scilex Holding Co was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +25.7% | +56.8% (7yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +25.7% over three years. Forward estimates point to Revenue at +56.8% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
Alector, Inc.
NASDAQ:ALEC
$169.87M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Agenus Inc.
NASDAQ:AGEN
$137.42M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Seer, Inc.
NASDAQ:SEER
$94.57M
Citius Oncology, Inc.
NASDAQ:CTOR
$61.74M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Incannex Healthcare Limited
IXHL
$43.99M
VistaGen Therapeutics, Inc.
VTGN
$18.88M
Who manages SCLX?
Scilex Holding Company (SCLX) lists 6 active executives. The top listed executive is Stephen Ma, Senior Vice President, Chief Financial Officer, Chief Operating Officer, Corporate Secretary & Director.
Are SCLX insiders buying or selling?
Recent insider activity shows net selling of $746.79M.
Explore More
Continue the stock analysis
Jump to another research area for this company.